Stevanato Group S.p.A. (STVN) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

$0.16

Estimate

$0.15

Surprise

+9.8%

Score at report (before → after)

4.9 → 4.9/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Stevanato Group S.p.A. (STVN) beat the $0.15 estimate with diluted EPS of $0.16 — a clear 9.8% upside surprise. TrendMatrix's engine moved from Buy (Wait) (4.9/10) to Sell at 4.9/10 after the report.

TrendMatrix currently rates STVN Sell at 4.6/10.

3 of the last 4 quarters beat the estimate; this quarter's +9.8% surprise compares with a +8.7% four-quarter average. Next scheduled report: 2026-11-05.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$20.42

Price target

$21.60

Stop

$19.39

Upside to target

+5.8%

Reward-to-risk

0.8:1

Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Medical Instruments & Supplies

Market cap

$5.61B

P/E (fwd)

24.4

P/E (ttm)

36.7

52-week range

$12.89–$28.00

Off 52-week high

27.1%

RSI (14)

42

Volume vs avg

0.11×

Score today

4.6/10